DeepHealth Brain (Neuro Suite)
Assess and monitor neurodegenerative changes
Software · Cloud SaaSCompany source
Company profile
About Aidence
Aidence was founded in 2015 as a radiology AI company focused on clinical solutions for pulmonary nodule management in routine practice and lung cancer screening. The company developed and deployed AI clinical applications to empower radiologists and other physicians in interpreting medical images. In 2022, Aidence was acquired by RadNet, Inc., a leading provider of diagnostic imaging in the United States, and subsequently integrated into DeepHealth, a wholly owned subsidiary of RadNet. Their flagship product, Veye Lung Nodules (now rebranded as DeepHealth Lung), is an AI-based solution for lung nodule detection, classification, quantification, and growth assessment, which received CE marking in Europe in 2017. As part of DeepHealth, the company continues its mission to push the boundaries of what's possible in healthcare by leveraging advanced AI to enable operational efficiency, clinical confidence, and better delivery of care. DeepHealth now offers a comprehensive portfolio including Enterprise Imaging solutions (Diagnostic Suite, Operations Suite, TechLive) and Population Health solutions covering breast, prostate, chest, neuro, and thyroid imaging. The company serves healthcare institutions worldwide with human-centered, intuitive technology designed to elevate the experience for care teams while improving diagnostic accuracy and workflow efficiency.
Company description Aidence official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Aidence?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Lung cancer
- Neurodegenerative diseases
- Prostate cancer
- Pulmonary nodules
- Thyroid conditions
Who it serves
- Diagnostic Imaging Centers
- Health Systems
- Hospitals
- Radiology Practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: fusion biopsy systems, Imagine billing and revenue cycle management platform, PACS, RIS.
Geographic context
MarketsEurope · Global · United States
Company sourceOfficial website
Company milestones
Platform expansion
2022: Acquired by RadNet, Inc.; 2023: Integrated into DeepHealth; Rebranding of Veye Lung Nodules to DeepHealth Lung; Expansion of product portfolio to include comprehensive imaging suites
Partnerships
Recorded partners
- Imagine Software
- RadNet, Inc. (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
DeepHealth Lung (formerly Veye Lung Nodules)
AI-powered nodule detection, reporting, and patient management for lung cancer diagnosis
Software · Cloud SaaSCompany source
DeepHealth Prostate (Prostate Suite)
Enhanced prostate cancer detection with fusion biopsy compatibility
Software · Cloud SaaSCompany source
Diagnostic Suite
Unified diagnostic workspace with PACS functionality and smart interpretation
Platform · Cloud SaaSCompany source
Operations Suite
Unified workspace for smart operations with RIS functionality
Platform · Cloud SaaSCompany source
SmartMammo (Breast Suite)
Enhanced workflow and diagnostic accuracy in breast cancer detection
Software · Cloud SaaSCompany source
TechLive
Multi-modality remote acquisition and collaboration platform
Platform · Cloud SaaSCompany source
Thyroid Suite
AI-powered end-to-end solution for thyroid ultrasound imaging
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Is the generalizability of a developed artificial intelligence algorithm for COVID-19 on chest CT sufficient for clinical use? Results from the International Consortium for COVID-19 Imaging AI (ICOVAI).European radiology · Jun 1, 2023
Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules on CT.European journal of radiology open · Jan 1, 2022
Validation of a deep learning computer aided system for CT based lung nodule detection, classification, and growth rate estimation in a routine clinical population.PloS one · Jan 1, 2022
Pulmonary nodule detection in CT scans with equivariant CNNs.Medical image analysis · Jul 1, 2019
Clinical validation
Clinical-trial records
Clinical Performance Evaluation of Veye Lung NodulesNCT04792632 · Sponsor · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Enhanced efficiency and accuracy in lung cancer diagnosis
AI-powered nodule detection, reporting, and patient management
Improved diagnostic accuracy
Enhanced workflow and diagnostic accuracy in breast cancer detection
Operational efficiency
Real-time workflow management and streamlined operations
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Aidence
Recent articles published on Aidence's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.